Xarelto... should I?

Discussion in 'Johnson & Johnson' started by Anonymous, Jun 29, 2011 at 12:35 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    I sold Lovenox for years and Multaq since launch... I have done well in my career, won multiple awards in a very tough territory over the last few years & more than half of my years in Pharma sales have come with awards. I have been approached by J&J for a position selling Xarelto for the CV position. It seems that Xarelto could be Lovenox in pill form. It may get many of the same indications and it has a long pat. life (12 years) vs 5 for Multaq. Even with all of that it wouldn't be an easy decision for me because SA has been good to me and I have many good friends here & great relationships with DM & RD. Add to that seniority, regional leadership positions, 32 Vacation/Personal days along with many other positives at SA. The money would be a little better, J&J seems a little safer (pipeline, future opportunity & stability) but starting over is not easy & my quality of life and the culture of a company are VERY important to me in my career decisions.

    How is J&J to work for?

    Am I looking at Xerelto properly?

    Is J&J flexible with their offers, do they negotiate their Vacation?

    What type of Cars are offered, I know this sounds petty but my previous 2 company cars caused massive back pain and SA provided a bigger better car that alleviated it, so to me it is very important.

    Thanks for your response!
     

  2. Anonymous

    Anonymous Guest

    stay where you are. Sounds like you have a solid dynamic now and you'd be walking into a very tenuous situation. Xarelto is not all that you are being told. And J&J is struggling on multiple fronts. You need to make a move up and you're only hoping to get to parity.
     
  3. Anonymous

    Anonymous Guest

    Xarelto cannot even begin to compete with Pradaxa, which is already becoming the clear market leader when you compare data to the Xa- inhibitors. Stay where you are, Xarelto is a flash in news, but wont amount to much otherwise.